This page contains a Flash digital edition of a book.
Sponsored content – Interview


Interview with Dr Xiong


Interview was conducted by Bethany Small, Commissioning Editor of Bioanalysis


Lei Xiong received her PhD degree in Analytical Chemistry from University of California Riverside, where she focused on MS applications for quantitative proteomics and protein characterization. After graduation, she joined Shimadzu Corporation as an LC-MS demo Scientist. In 2011, she joined SCIEX as application scientist supporting method development, demo, training, and field support in biopharmaceutical and academic applications.


Q Could you tell us a little about your career to date & how you ended up in


your current role? As an analytical chemist, I came to SCIEX with a background in quantitative proteomics and protein characterization using MS. Since 2011 I have worked as an application scientist directly working with our customers in both the pharmaceutical industry and in academia by teaching advanced MS training courses, and providing on-site support. In 2015, I transitioned to become the Group


Leader of an advanced workflow development team, which is focused on the development and testing of new quantitative methods using MS. My team of application scientists and I strive to create robust quantitative solutions that cover entire workflows, from sample preparation to LC-MS/MS analysis to data processing and reporting. Additionally, I am the Global Lead Scientist for biotherapeutic peptide quantitation for SCIEX, which means I act as the interface between our customers and the SCIEX R&D team to ensure the bio- analytical challenges of today are driving the solutions of tomorrow.


Q What are you working on at the moment?


My team’s work this year is focused on MS- based method and solution development.


10.4155/bio.16.2 © 2016 Future Science Ltd


One important area we’ve targeted our efforts is in large molecule bioanalysis, for example, hybrid ligand-binding assay (LBA)–LC-MS/ MS methods for peptide and protein quanti- tation in biological matrices. We’ve success- fully combined immunocapture-based sam- ple preparation with the industry standard triple quadrupole based LC-MS/MS systems to provide high-throughput, sensitive, repro- ducible solutions. These methods allow our customers to set-up and execute large mole- cule screening, quantitation and PK profiling projects at a pace not previously achievable. Our goal is to bring together a complete solu- tion that


links reagents, methods, instru-


mentation, automation and software, so our customers can get to their important answers faster and with better accuracy. This works is very exciting, and more information, includ- ing details on our therapeutic antibody and insulin analog methods, can be found at www.sciex.com/biobasolution.


Progress & obstacles in 2015


Q What would you say were the bioanalytical highlights of 2015? Some of the notable bioanalytical high- lights from 2015 were the increased atten- tion around routine use of hybrid-LBA–LC/ MS technology, advancements in method


Bioanalysis (2016) ISSN 1757-6180


Lei Xiong SCIEX, 1201 Radio Road, Redwood City, CA, 94065, USA lei.xiong@sciex.com


part of


105


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154